J&J buys into spine test firm
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson leads a $15.3 million financing round and enters a strategic collaboration with Axial Biotech to accelerate the start-up's development of a genetic test to pre-symptomatically predict which cases of scoliosis, or abnormal curvature of the spine, are likely to progress and require intervention, firms announce March 27. Axial hopes to launch the first-of-its-kind test in late 2008, and estimates a U.S. market size of $180 million. The Raynham, Mass. firm also is developing minimally invasive devices for spine surgery...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.